• 1
    Stanner SA, Hughes J, Kelly CN, Buttriss J. A review of the epidemiological evidence for the ‘antioxidant hypothesis’. Public Health Nutr 2004; 7: 40722.
  • 2
    Stocker R. Antioxidant activities of bile pigments. Antioxid Redox Signal 2004; 6: 8419.
  • 3
    Novotný L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 2003; 228: 56871.
  • 4
    Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem 2010; 56: 153543.
  • 5
    Kronenberg F. Association of bilirubin with cardiovascular outcomes: more hype than substance? Circ Cardiovasc Genet 2010; 3: 30810.
  • 6
    Ekblom K, Marklund SL, Jansson JH et al. Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting. Circ Cardiovasc Genet 2010; 3: 3407.
  • 7
    Timpson NJ, Wade KH, Smith GD. Mendelian randomization: application to cardiovascular disease. Curr Hypertens Rep 2012; 14: 2937.
  • 8
    Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 11715.
  • 9
    Johnson AD, Kavousi M, Smith AV et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 2009; 18: 270010.
  • 10
    Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897908.
  • 11
    Frikke-Schmidt R, Nordestgaard BG, Stene MC et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008; 299: 252432.
  • 12
    Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 2002; 23: 6206.
  • 13
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499502.
  • 14
    Bosma PJ, van der Meer IM, Bakker CT, Hofman A, Paul-Abrahamse M, Witteman JC. UGT1A1*28 allele and coronary heart disease: the Rotterdam Study. Clin Chem 2003; 49: 11801.
  • 15
    Chen YH, Hung SC, Tarng DC. Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 56774.
  • 16
    Gajdos V, Petit FM, Perret C et al. Further evidence that the UGT1A1*28 allele is not associated with coronary heart disease: the ECTIM Study. Clin Chem 2006; 52: 23134.
  • 17
    Lin JP, O'Donnell CJ, Schwaiger JP et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006; 114: 147681.
  • 18
    Lingenhel A, Kollerits B, Schwaiger JP et al. Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease. Exp Gerontol 2008; 43: 11027.
  • 19
    Rantner B, Kollerits B, Anderwald-Stadler M et al. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin Chem 2008; 54: 8517.
  • 20
    Lin R, Wang Y, Wang Y et al. Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population. Pharmacogenet Genomics 2009; 19: 3108.
  • 21
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 55760.
  • 22
    Ekblom K, Marklund SL, Johansson L et al. Bilirubin and UGT1A1*28 are not associated with lower risk for ischemic stroke in a prospective nested case-referent setting. Cerebrovasc Dis 2010; 30: 5906.
  • 23
    Hsieh CJ, Chen MJ, Liao YL, Liao TN. Polymorphisms of the uridine-diphosphoglucuronosyltransferase 1A1 gene and coronary artery disease. Cell Mol Biol Lett 2008; 13: 110.
  • 24
    Papez MJ, Civalier CJ, Thorne LB, Gulley ML. UGT1A1 promoter genotype is not strongly associated with severity of coronary artery disease. Diagn Mol Pathol 2009; 18: 22631.
  • 25
    Musunuru K, Kathiresan S. Genetics of coronary artery disease. Annu Rev Genomics Hum Genet 2010; 11: 91108.
  • 26
    Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 2001; 87: 1196200.
  • 27
    Troughton JA, Woodside JV, Young IS et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil 2007; 14: 7984.
  • 28
    Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995; 41: 15048.
  • 29
    Ekblom K, Marklund SL, Jansson JH et al. Response to letter regarding article, “Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting”. Circ Cardiovasc Genet 2011; 4: e1.
  • 30
    Allen LA, Felker GM, Pocock S et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009; 11: 1707.
  • 31
    Ong KL, Wu BJ, Cheung BM, Barter PJ, Rye KA. Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999–2008. Atherosclerosis 2011; 219: 72833.
  • 32
    Strassburg CP. Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg? Drug Metab Rev 2010; 42: 16881.
  • 33
    Schwertner HA. Association of smoking and low serum bilirubin antioxidant concentrations. Atherosclerosis 1998; 136: 3837.
  • 34
    Lin LY, Kuo HK, Hwang JJ et al. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009; 203: 5638.
  • 35
    Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999; 12: 67381.
  • 36
    Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA 2009; 106: 51716.
  • 37
    Horsfall LJ, Rait G, Walters K et al. Serum bilirubin and risk of respiratory disease and death. JAMA 2011; 305: 6917.
  • 38
    Timpson NJ, Forouhi NG, Brion MJ et al. Genetic variation at the SLC23A1 locus is associated with circulating concentrations of l-ascorbic acid (vitamin C): evidence from 5 independent studies with >15,000 participants. Am J Clin Nutr 2010; 92: 37582.
  • 39
    Bulmer AC, Blanchfield JT, Toth I, Fassett RG, Coombes JS. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 2008; 199: 3906.
  • 40
    Owens D, Sherlock S. Diagnosis of Gilbert's syndrome: role of reduced caloric intake test. Br Med J 1973; 3: 55963.